← Back to Search

Integrin Antagonist

nanomicellular cyclosporine 0.09% for Dry Eye Syndrome

Phase 4
Recruiting
Research Sponsored by Toyos Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights

Summary

This trial is testing two types of eye drops to see which one is better at clearing and healing the surface of the eye in adults aged 18-85 who have corneal staining.

Eligible Conditions
  • Dry Eye Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
change in central corneal staining
Secondary study objectives
change in OSDI questionnaire with additional questions of dysgeusia, blurriness and sensation of burning
change in Schirmers testing
change in corneal topography

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Nanomicellular Cyclosporine 0.09 prior to surgeryExperimental Treatment1 Intervention
50 subjects receive nanomicellular cyclosporien 0.09% prior to elective ophthalmic surgery
Group II: Lifitegrast 5.0%Active Control1 Intervention
50 subjects receive liftigrast 5.0% prior to elective ophthalmic surgery

Find a Location

Who is running the clinical trial?

Toyos ClinicLead Sponsor
8 Previous Clinical Trials
160 Total Patients Enrolled
Sun Pharmaceutical Industries LimitedIndustry Sponsor
68 Previous Clinical Trials
13,503 Total Patients Enrolled
~18 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top